Thrombocytopenia is among the strongest predictors of decreased survival for patients with myelodysplastic syndromes (MDS) across all prognostic risk groups. The safety and efficacy of CC-486 (oral azacitidine) was investigated in early-phase studies; we assessed clinical outcomes among subgroups of MDS...
Thrombocytopenia is among the strongest predictors of decreased survival for patients with myelodysplastic syndromes (MDS) across all prognostic risk groups. The safety and efficacy of CC-486 (oral azacitidine) was investigated in early-phase studies; we assessed clinical outcomes among subgroups of MDS...
Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS). IMM01联合阿扎胞苷(AZA)用于成人高危骨髓增生异常综合征(MDS)...
Patients were not eligible for participation if they had received prior treatment with more than 1 cycle of azacitidine or decitabine, treatment with any investigational therapy within 2 weeks of receiving the study treatment, or treatment with any concurrent MDS therapies.3 REFERENCES: 1. Taiho ...
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS) 中文标题:IMM01联合阿扎胞苷(AZA)一线治疗成人高危骨髓...
AML, acute myeloid leukemia; AZA, azacitidine; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS Int-2, International Prognostic Scoring System intermediate 2; MDS, myelodysplastic syndrome; MTD, maximum tolerated dose; PAN, panobinostat; RP2D, ...
In an attempt to counter chemo-resistant DLBCL, Peter Martin, MD, along with several other colleagues at Weil Cornell Medicine, set out to test alternative therapies for such patients with a phase I, open-label, multicenter trial of oral azacitidine (Vidaza) plus R-CHOP in people with hig...
Uses for ivosidenibIvosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy). It is also used to treat ...
(MDS).S791 The next talk was given by the co-chair of this session, Professor Charles Craddock, discussing results from the UK Trials Acceleration Programme RAvVA randomized phase II study (NCT01617226), which compared monotherapy with the Hypomethylating Agent (HMA) azacitidine (AZA) with AZA...
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML). -- Garcia-Manero et al... G Garciamanero,SD Gore,B Skikne,... 被引量: 37发...